Loading...

Five Prime Therapeutics

DB:5P8
Snowflake Description

Flawless balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
5P8
DB
$430M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The last earnings update was 55 days ago. More info.


Add to Portfolio Compare Print
5P8 Share Price and Events
7 Day Returns
-4.6%
DB:5P8
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
-19.7%
DB:5P8
-10.2%
DE Biotechs
-6%
DE Market
5P8 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Five Prime Therapeutics (5P8) -4.6% -10.1% 7.4% -19.7% -75% 2.6%
DE Biotechs -2.4% 3.8% -8.6% -10.2% 51.2% 10.1%
DE Market 1.8% 6% 7.8% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • 5P8 underperformed the Biotechs industry which returned -10.2% over the past year.
  • 5P8 underperformed the Market in Germany which returned -6% over the past year.
Price Volatility
5P8
Industry
5yr Volatility vs Market
Related Companies

5P8 Value

 Is Five Prime Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Five Prime Therapeutics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Five Prime Therapeutics.

DB:5P8 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 9 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:5P8
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.448 (1 + (1- 21%) (0%))
1.3
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.3
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.3 * 5.96%)
7.98%

Discounted Cash Flow Calculation for DB:5P8 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Five Prime Therapeutics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:5P8 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 7.98%)
2019 -114.90 Analyst x3 -106.41
2020 -108.28 Analyst x3 -92.87
2021 -131.16 Analyst x3 -104.19
2022 -16.97 Analyst x2 -12.48
2023 18.53 Analyst x2 12.62
2024 27.88 Est @ 50.47% 17.59
2025 37.75 Est @ 35.4% 22.06
2026 47.13 Est @ 24.85% 25.51
2027 55.36 Est @ 17.46% 27.75
2028 62.17 Est @ 12.29% 28.86
Present value of next 10 years cash flows $-181.56
DB:5P8 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $62.17 × (1 + 0.23%) ÷ (7.98% – 0.23%)
$804.21
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $804.21 ÷ (1 + 7.98%)10
$373.34
DB:5P8 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $-181.56 + $373.34
$191.78
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $191.78 / 36.06
$5.32
DB:5P8 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:5P8 represents 0.8825x of NasdaqGS:FPRX
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.8825x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 5.32 x 0.8825
€4.69
Value per share (EUR) From above. €4.69
Current discount Discount to share price of €10.44
= -1 x (€10.44 - €4.69) / €4.69
-122.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Five Prime Therapeutics is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Five Prime Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Five Prime Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:5P8 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-4.13
NasdaqGS:FPRX Share Price ** NasdaqGS (2019-04-18) in USD $11.83
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Five Prime Therapeutics.

DB:5P8 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:FPRX Share Price ÷ EPS (both in USD)

= 11.83 ÷ -4.13

-2.86x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Five Prime Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Five Prime Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Five Prime Therapeutics's expected growth come at a high price?
Raw Data
DB:5P8 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.86x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts
19%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Five Prime Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Five Prime Therapeutics's assets?
Raw Data
DB:5P8 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $7.63
NasdaqGS:FPRX Share Price * NasdaqGS (2019-04-18) in USD $11.83
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:5P8 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:FPRX Share Price ÷ Book Value per Share (both in USD)

= 11.83 ÷ 7.63

1.55x

* Primary Listing of Five Prime Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Five Prime Therapeutics is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Five Prime Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Five Prime Therapeutics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

5P8 Future Performance

 How is Five Prime Therapeutics expected to perform in the next 1 to 3 years based on estimates from 9 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
19%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Five Prime Therapeutics expected to grow at an attractive rate?
  • Unable to compare Five Prime Therapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Five Prime Therapeutics's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Five Prime Therapeutics's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:5P8 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:5P8 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts 19%
DB:5P8 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 9 Analysts 31.6%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:5P8 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:5P8 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 215 56 -23 6
2022-12-31 139 40 -100 6
2021-12-31 115 -135 -108 7
2020-12-31 72 -105 -113 9
2019-12-31 32 -110 -134 8
DB:5P8 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 50 -123 -140
2018-09-30 59 -97 -131
2018-06-30 62 -94 -127
2018-03-31 62 -95 -137
2017-12-31 40 -112 -150
2017-09-30 35 -100 -141
2017-06-30 33 -88 -117
2017-03-31 34 -74 -86
2016-12-31 31 -80 -66
2016-09-30 386 269 251
2016-06-30 385 260 246
2016-03-31 382 266 248

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Five Prime Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Five Prime Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:5P8 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below

All data from Five Prime Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:5P8 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -0.34 1.77 -1.41 6.00
2022-12-31 -1.53 -0.46 -2.83 6.00
2021-12-31 -2.28 -0.87 -3.71 7.00
2020-12-31 -2.84 -1.54 -3.67 9.00
2019-12-31 -3.95 -3.35 -5.96 8.00
DB:5P8 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -4.13
2018-09-30 -4.05
2018-06-30 -4.13
2018-03-31 -4.71
2017-12-31 -5.38
2017-09-30 -5.08
2017-06-30 -4.26
2017-03-31 -3.16
2016-12-31 -2.44
2016-09-30 9.42
2016-06-30 9.36
2016-03-31 9.53

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Five Prime Therapeutics will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Five Prime Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Five Prime Therapeutics has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

5P8 Past Performance

  How has Five Prime Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Five Prime Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Five Prime Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Five Prime Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Five Prime Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Five Prime Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Five Prime Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:5P8 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 49.87 -140.45 39.67
2018-09-30 59.06 -130.91 40.57
2018-06-30 61.62 -126.94 40.41
2018-03-31 61.86 -137.17 39.99
2017-12-31 39.51 -150.22 40.00
2017-09-30 34.55 -141.12 40.05
2017-06-30 32.90 -117.25 39.52
2017-03-31 34.31 -86.10 38.26
2016-12-31 30.69 -65.70 35.83
2016-09-30 385.77 250.54 33.91
2016-06-30 384.95 245.98 29.98
2016-03-31 382.03 247.64 26.47
2015-12-31 379.80 249.65 22.63
2015-09-30 21.11 -58.31 18.00
2015-06-30 21.31 -41.42 16.14
2015-03-31 19.97 -39.82 14.57
2014-12-31 19.23 -37.42 13.63
2014-09-30 18.37 -32.92 12.71
2014-06-30 15.79 -33.06 11.95
2014-03-31 14.36 -30.47 11.32
2013-12-31 13.79 -28.87 10.43
2013-09-30 12.93 -28.37 9.70
2013-06-30 12.31 -26.99 9.35
2013-03-31 10.86 -27.18 9.18
2012-12-31 9.98 -27.60 9.01

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Five Prime Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Five Prime Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Five Prime Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Five Prime Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Five Prime Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

5P8 Health

 How is Five Prime Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Five Prime Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Five Prime Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Five Prime Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Five Prime Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Five Prime Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Five Prime Therapeutics Company Filings, last reported 3 months ago.

DB:5P8 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 265.14 0.00 270.14
2018-09-30 296.78 0.00 321.60
2018-06-30 336.86 0.00 352.77
2018-03-31 362.22 0.00 389.43
2017-12-31 265.20 0.00 292.69
2017-09-30 286.09 0.00 320.76
2017-06-30 323.27 0.00 350.72
2017-03-31 357.05 0.00 380.32
2016-12-31 391.58 0.00 421.75
2016-09-30 403.98 0.00 440.70
2016-06-30 426.70 0.00 469.23
2016-03-31 428.14 0.00 481.99
2015-12-31 433.21 0.00 517.47
2015-09-30 125.64 0.00 183.41
2015-06-30 145.92 0.00 207.41
2015-03-31 154.77 0.00 217.14
2014-12-31 85.21 0.00 149.05
2014-09-30 94.86 0.00 129.98
2014-06-30 100.91 0.00 140.58
2014-03-31 109.32 0.00 128.93
2013-12-31 58.03 0.00 75.72
2013-09-30 64.71 0.00 86.64
2013-06-30 7.20 0.00 28.20
2013-03-31 20.40 0.00 38.02
2012-12-31 20.40 0.00 38.02
  • Five Prime Therapeutics has no debt.
  • Five Prime Therapeutics has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Five Prime Therapeutics has sufficient cash runway for 2 years based on current free cash flow.
  • Five Prime Therapeutics has sufficient cash runway for 1.6 years if free cash flow continues to grow at historical rates of 100.8% each year.
X
Financial health checks
We assess Five Prime Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Five Prime Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

5P8 Dividends

 What is Five Prime Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Five Prime Therapeutics dividends. Estimated to be 0% next year.
If you bought €2,000 of Five Prime Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Five Prime Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Five Prime Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:5P8 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:5P8 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 2.00
2019-12-31 0.00 2.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Five Prime Therapeutics has not reported any payouts.
  • Unable to verify if Five Prime Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Five Prime Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Five Prime Therapeutics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Five Prime Therapeutics's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Five Prime Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Five Prime Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Five Prime Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

5P8 Management

 What is the CEO of Five Prime Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Aron Knickerbocker
COMPENSATION $7,134,227
AGE 49
TENURE AS CEO 1.3 years
CEO Bio

Mr. Aron Marc Knickerbocker has served as the President and Chief Executive Officer of Five Prime Therapeutics, Inc. since January 1, 2018. Mr. Knickerbocker served as the Chief Operating Officer of Five Prime Therapeutics, Inc. since September 8, 2016. Mr. Knickerbocker served as the Chief Business Officer of Five Prime Therapeutics, Inc. from April 2012 to September 2016 and as its Executive Vice President from August 2015 to September 2016. Mr. Knickerbocker served as Senior Vice President of Five Prime Therapeutics, Inc. from April 2012 to August 17, 2015 and as its Vice President of Business Development from October 2009 to April 2012. He has substantial experience in business development licensing and corporate development. Mr. Knickerbocker leads FivePrime's business development and licensing activities to accelerate advancement of its drug pipeline and continue to mine its robust discovery platform for innovative biologics. Mr. Knickerbocker joined FivePrime from Genentech, Inc. From 2001 to September 2009, Mr. Knickerbocker served at Genentech in positions of increasing responsibility most recently as Senior Director, Business Development from 2005 to September 2009. Prior to 2001, Mr. Knickerbocker served as Director of Commercial Development at ALZA, a pharmaceutical company acquired by Johnson & Johnson, as Senior Manager, Corporate Development at Amgen, and as a scientist at Bristol-Myers Squibb. He began his career in the biopharmaceutical industry in research as a scientist at Bristol-Myers Squibb. He has been a Director of Five Prime Therapeutics, Inc. since October 23, 2013. Mr. Knickerbocker received his B.A. degree in biology from Washington University in St. Louis and his M.B.A. degree from the University of Michigan.

CEO Compensation
  • Aron's compensation has increased whilst company is loss making.
  • Aron's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Five Prime Therapeutics management team in years:

1.2
Average Tenure
54
Average Age
  • The average tenure for the Five Prime Therapeutics management team is less than 2 years, this suggests a new team.
Management Team

Aron Knickerbocker

TITLE
President
COMPENSATION
$7M
AGE
49
TENURE
1.3 yrs

Francis Sarena

TITLE
Chief Strategy Officer & Secretary
COMPENSATION
$3M
AGE
47

Helen Collins

TITLE
Senior VP & Chief Medical Officer
COMPENSATION
$3M
AGE
55
TENURE
2.1 yrs

Peder Jensen

TITLE
Advisor & Director
COMPENSATION
$244K
AGE
63

David Smith

TITLE
Executive VP & CFO
TENURE
0.4 yrs

David White

TITLE
Principal Accounting Officer
AGE
54
TENURE
0.2 yrs

Martin Forrest

TITLE
Vice President of Investor Relations & Corporate Communications

Bryan Irving

TITLE
Executive VP & Chief Scientific Officer
AGE
54
TENURE
1.6 yrs

Nallakkan Arvindan

TITLE
Senior Vice President of Strategic Technology Operations
TENURE
1.2 yrs
Board of Directors Tenure

Average tenure and age of the Five Prime Therapeutics board of directors in years:

4.4
Average Tenure
66
Average Age
  • The tenure for the Five Prime Therapeutics board of directors is about average.
Board of Directors

Bill Ringo

TITLE
Chairman of the Board
COMPENSATION
$232K
AGE
73
TENURE
0.3 yrs

Aron Knickerbocker

TITLE
President
COMPENSATION
$7M
AGE
49
TENURE
5.5 yrs

Peder Jensen

TITLE
Advisor & Director
COMPENSATION
$244K
AGE
63
TENURE
7.8 yrs

Kapil Dhingra

TITLE
Director
COMPENSATION
$229K
AGE
59
TENURE
3.3 yrs

Garry Nicholson

TITLE
Director
COMPENSATION
$302K
AGE
63
TENURE
1.9 yrs

Rusty Williams

TITLE
Founder & Director
COMPENSATION
$5M
AGE
69
TENURE
17.3 yrs

Art Weiss

TITLE
Member of Scientific Advisory Board

Ron Levy

TITLE
Member of Scientific Advisory Board

Robert Lefkowitz

TITLE
Member of Scientific Advisory Board
AGE
74

Joseph Goldstein

TITLE
Member of Scientific Advisory Board
AGE
78
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Five Prime Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Five Prime Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

5P8 News

Simply Wall St News

5P8 Company Info

Description

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company’s product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase III clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28. Its product candidates also include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor. The company’s BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in clinical trial as a single agent and in combination with Opdivo in patients with advanced malignant tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company, GlaxoSmithKline LLC, INBRX 110 LP, UCB Pharma S.A., and Zai Lab (Shanghai) Co., Ltd.; a collaboration agreement with Roche; and license agreements with Galaxy Biotech, LLC, BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California.

Details
Name: Five Prime Therapeutics, Inc.
5P8
Exchange: DB
Founded: 2001
$381,504,181
36,064,239
Website: http://www.fiveprime.com
Address: Five Prime Therapeutics, Inc.
111 Oyster Point Boulevard,
South San Francisco,
California, 94080,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS FPRX Common Stock Nasdaq Global Select US USD 18. Sep 2013
DB 5P8 Common Stock Deutsche Boerse AG DE EUR 18. Sep 2013
Number of employees
Current staff
Staff numbers
210
Five Prime Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/22 21:58
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/11
Last earnings filing: 2019/02/26
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.